Don't Miss

New tests for efficient anaemia therapies

By on August 13, 2015

Innovative therapeutic protein could advance into better treatment for chronic anaemia suffering patients


The EUROCALIN project is an EU-funded project started in August 2011. The trial evaluates the safety and tolerability rates of the PRS 080 protein in healthy subjects. Researchers hope to find a cure for non-responsive to treatment chronic anaemia patients. The EUROCALIN clinical trial will complete at the end of 2015.

Anaemia is a significant health issue that is characterized by red blood cells deficiency, low haemoglobin levels, pale skin, fatigue and weariness. Also, this condition is often linked to low levels of iron. As iron deficiency anaemia is the most common type of anaemia, the new therapy focuses on mobilising iron from the cells. If PRS-080 proves successful, chronic anaemia diseased patients will highly benefit from the therapy, as 10% of the people suffering from this condition do not respond to classic ESA therapy (administration of red blood cells stimulating substances called erythropoiesis-stimulating agents).

The project brought together ten companies and academic institutions from across Europe to manage the first stages of clinical evaluation. A small peptide found in human blood, called hepcidin negatively affects iron stability in the body. By blocking it, PRS-080 increases iron levels in the blood, thus increases haemoglobin levels in patients suffering from anaemia.

48 healthy subjects participate in the placebo-controlled, blinded study. Trial results are still being assessed.

EUROCALIN project team and partners hope that the trial will result in safe and effective treatments for chronic anaemia and help in the future developing of similar protein-based therapies for anaemia, but also for other illnesses.






About Laura Parvan

Medical professional, blogging passionate, with a high interest in social media impact on health-care information.

Leave a Reply

Your email address will not be published.